Merck Investors Win Class Cert. In 2 Suits Over Vytorin

Law360, New York (September 26, 2012, 6:23 PM EDT) -- A New Jersey federal judge on Tuesday granted class certification in a pair of related suits brought by investors claiming drugmaker Merck & Co. and subsidiary Schering-Plough hid test results that showed their anti-cholesterol drug Vytorin did not work.

U.S. District Judge Dennis M. Cavanaugh said the plaintiffs, large institutional investors, had put forward enough evidence that the alleged concealment harmed their shareholders a whole.

“Plaintiffs have sufficiently demonstrated the existence of a causal relationship between the announcement of unexpected news and an immediate response in...
To view the full article, register now.